Genomics-driven drug discovery based on disease-susceptibility genes

Area of Science:

• Genetics
• Pharmacology
• Bioinformatics

Background:

• Genome-wide association studies (GWAS) have identified numerous disease-susceptibility genes.
• Translating genetic discoveries into clinical practice remains a significant challenge.
• Identifying effective drug targets and predicting side effects are crucial for successful clinical trials.

Purpose of the Study:

• To review recent advances in genetics-led drug discovery.
• To explore future perspectives in this field.
• To highlight key methodologies like drug repurposing, Mendelian randomization, and omics data integration.

Main Methods:

• Review of recent scientific literature.
• Focus on genetics-led drug discovery approaches.
• Discussion of drug repurposing strategies.
• Explanation of Mendelian randomization principles.
• Integration of multifaceted omics data.

Main Results:

• Accumulating knowledge of gene-disease associations.
• Identification of challenges in translating genetic findings to clinical practice.
• Highlighting the potential of genetics to guide drug target identification.
• Demonstrating the utility of drug repurposing, Mendelian randomization, and omics data.

Conclusions:

• Genetics-led drug discovery offers a promising avenue for developing effective therapeutics.
• Overcoming challenges in clinical translation requires innovative approaches.
• The integration of diverse data types, including omics data, is essential for advancing the field.